Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Entrectinib Breaks Through With Japanese Approval for NTRK-Positive Tumors

June 18th 2019

Entrectinib received its first regulatory approval, as Japan’s Ministry of Health, Labour and Welfare has approved the drug for the treatment of adult and pediatric patients with NTRK fusion–positive, advanced recurrent solid tumors.

Evolutions in the Treatment of EGFR-Mutated NSCLC

June 4th 2019

Sequencing With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Second- and Third-Generation TKIs in EGFR-Mutated NSCLC

June 4th 2019

Treating With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Resistance to Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

June 4th 2019

Expert Shares Advantages, Challenges With Liquid Biopsies in Cancer Care

May 23rd 2019

Geoffrey Oxnard, MD, discusses testing error underlying liquid biopsy discordance, steps clinicians can take to optimize liquid biopsy, and where he sees this evolving in the treatment landscape for patients with cancer.

TLR Agonists Emerge as Potential New Partner for Checkpoint Inhibitors

May 15th 2019

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

Dr. Papadimitrakopoulou on the Utility of Liquid Biopsies in NSCLC

May 11th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses the utility of liquid biopsies in non–small cell lung cancer (NSCLC).

Genomic Assays Continue to Individualize Treatment for HR+ Breast Cancer

May 7th 2019

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Role of Liquid Biopsies Still Needs Refining in Breast Cancer

April 25th 2019

Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.

Precision Medicine in Oncology: Overcoming Obstacles

April 19th 2019

Genomic Profiling in Solid Tumor Malignancies: Challenges

April 19th 2019

Genomic Testing: Sarcoma, Lung Cancer and Thyroid Cancer

April 19th 2019

Genomic Testing: GI Tumors

April 19th 2019

Managing Patients on TRK Inhibitors

April 19th 2019

Entrectinib as Treatment for NTRK-Positive Solid Tumors

April 19th 2019

Larotrectinib for Solid Tumors With NTRK Gene Fusions

April 19th 2019

TRK Inhibitors for Solid Tumors: Overview

April 19th 2019